{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:01:42Z","timestamp":1757703702960,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s10067-021-05802-8","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T02:02:37Z","timestamp":1625364157000},"page":"5095-5102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world data on MTX tolerance with regimens used in children versus adults"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0426-9432","authenticated-orcid":false,"given":"Ummusen","family":"Kaya Akca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-1103","authenticated-orcid":false,"given":"Bayram","family":"Farisogullari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-4685","authenticated-orcid":false,"given":"Gozde Kubra","family":"Yardimci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-2656","authenticated-orcid":false,"given":"Erdal","family":"Sag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-7121","authenticated-orcid":false,"given":"Erdal","family":"Atalay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9957-8894","authenticated-orcid":false,"given":"Muserref","family":"Kasap Cuceoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-0930","authenticated-orcid":false,"given":"Ozge","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-9690","authenticated-orcid":false,"given":"Levent","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-7282","authenticated-orcid":false,"given":"Seza","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-0072","authenticated-orcid":false,"given":"Yelda","family":"Bilginer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"key":"5802_CR1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","volume":"50","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Murray KJ, Gerloni V, Wulffraat N, Feitosa De Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, Corona F (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191\u20132201","journal-title":"Arthritis Rheum"},{"key":"5802_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00393-009-0535-2","volume":"68","author":"C Fiehn","year":"2009","unstructured":"Fiehn C (2009) Methotrexat in der Rheumatologie. Z Rheumatol 68:747\u2013757","journal-title":"Z Rheumatol"},{"key":"5802_CR3","first-page":"1850","volume":"20","author":"R McKendry","year":"1993","unstructured":"McKendry R, Dale P (1993) Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 20:1850\u20131856","journal-title":"J Rheumatol"},{"key":"5802_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1590\/S0004-28032011000100016","volume":"48","author":"PM Soares","year":"2011","unstructured":"Soares PM, Lopes LO, Mota JMS, Belarmino-Filho JN, Ribeiro RA, de Souza MHL (2011) Methotrexate-induced intestinal mucositis delays gastric emptying and gastrointestinal transit of liquids in awake rats. Arq Gastroenterol 48:80\u201385","journal-title":"Arq Gastroenterol"},{"key":"5802_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10067-016-3243-8","volume":"35","author":"N Fatimah","year":"2016","unstructured":"Fatimah N, Salim B, Nasim A, Hussain K, Gul H, Niazi S (2016) Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire). Clin Rheumatol 35:1341\u20131345","journal-title":"Clin Rheumatol"},{"key":"5802_CR6","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/rheumatology\/keaa139","volume":"59","author":"B H\u00fcgle","year":"2020","unstructured":"H\u00fcgle B, van Dijkhuizen E (2020) MTX intolerance in children and adolescents with juvenile idiopathic arthritis. Rheumatology 59:1482\u20131488","journal-title":"Rheumatology"},{"key":"5802_CR7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/art.30367","volume":"63","author":"M Bulatovi\u0107","year":"2011","unstructured":"Bulatovi\u0107 M, Heijstek MW, Verkaaik M, van Dijkhuizen EP, Armbrust W, Hoppenreijs EP, Kamphuis S, Kuis W, Egberts TC, Sinnema G (2011) High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 63:2007\u20132013","journal-title":"Arthritis Rheum"},{"key":"5802_CR8","doi-asserted-by":"publisher","first-page":"R217","DOI":"10.1186\/ar4413","volume":"15","author":"MB \u0106alasan","year":"2013","unstructured":"\u0106alasan MB, van den Bosch OF, Creemers MC, Custers M, Heurkens AH, van Woerkom JM, Wulffraat NM (2013) Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther 15:R217","journal-title":"Arthritis Res Ther"},{"key":"5802_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-12-1","volume":"12","author":"AC Da Silva","year":"2014","unstructured":"Da Silva AC, Farias A, Sinicato N, Veloso R, Marini R, Appenzeller S (2014) Reasons for stopping methotrexate treatment in patients with juvenile idiopathic arthritis. Pediatr Rheumatol 12:1\u20131","journal-title":"Pediatr Rheumatol"},{"key":"5802_CR10","first-page":"625","volume":"17","author":"A Ravelli","year":"1999","unstructured":"Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A (1999) Efficacy of folinic arid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 17:625\u2013627","journal-title":"Clin Exp Rheumatol"},{"key":"5802_CR11","first-page":"480","volume":"25","author":"A Van der Meer","year":"2007","unstructured":"Van der Meer A, Wulffraat N, Prakken B, Gijsbers B, Rademaker C, Sinnema G (2007) Pediatric rheumatology psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 25:480\u2013485","journal-title":"Clin Exp Rheumatol"},{"key":"5802_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","volume":"36","author":"R Hamilton","year":"1997","unstructured":"Hamilton R, Kremer J (1997) Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 36:86\u201390","journal-title":"Br J Rheumatol"},{"key":"5802_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1590\/S0482-50042011000100003","volume":"51","author":"F Bagatini","year":"2011","unstructured":"Bagatini F, Blatt CR, Maliska G, Trespash GV, Pereira IA, Zimmermann AF, Storb BH, Farias MR (2011) Potential drug interactions in patients with rheumatoid arthritis. Rev Bras Reumatol 51:29\u201339","journal-title":"Rev Bras Reumatol"},{"key":"5802_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12969-015-0002-3","volume":"13","author":"EHP van Dijkhuizen","year":"2015","unstructured":"van Dijkhuizen EHP, \u0106alasan MB, Pluijm SM, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM (2015) Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study. Pediatr Rheumatol 13:5","journal-title":"Pediatr Rheumatol"},{"key":"5802_CR15","doi-asserted-by":"crossref","unstructured":"Fr\u00e1\u0148ov\u00e1 J, Fingerhutov\u00e1 \u0160, Kobrova K, Srp R, N\u011bmcov\u00e1 D, Hoza J, Uher M, Saifridov\u00e1 M, Linkov\u00e1 L, Dole\u017ealov\u00e1 P (2016) Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol 14:36","DOI":"10.1186\/s12969-016-0099-z"},{"key":"5802_CR16","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/rheumatology\/kev259","volume":"54","author":"TS Amin","year":"2015","unstructured":"Amin TS, Shenton S, Mulligan K, Wedderburn LR, Wood M, VanRooyen V, Leone V (2015) Strategies for the prevention and management of methotrexate-related nausea and vomiting in juvenile idiopathic arthritis: results of a UK paediatric rheumatology prescriber survey. Rheumatology 54:2108\u20132109","journal-title":"Rheumatology"},{"key":"5802_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42358-020-00145-5","volume":"60","author":"JM Amaral","year":"2020","unstructured":"Amaral JM, Brito MJM, Kakehasi AM (2020) High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS). Adv Rheumatol 60:1\u20136","journal-title":"Adv Rheumatol"},{"key":"5802_CR18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/1756-185X.12910","volume":"21","author":"P Dhaon","year":"2018","unstructured":"Dhaon P, Das SK, Srivastava R, Agarwal G, Asthana A (2018) Oral Methotrexate in split dose weekly versus oral or parenteral Methotrexate once weekly in Rheumatoid Arthritis: a short-term study. Int J Rheum Dis 21:1010\u20131017","journal-title":"Int J Rheum Dis"},{"key":"5802_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/adc.88.3.197","volume":"88","author":"A Ramanan","year":"2003","unstructured":"Ramanan A, Whitworth P, Baildam E (2003) Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 88:197\u2013200","journal-title":"Arch Dis Child"},{"key":"5802_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-018-0228-y","volume":"16","author":"L H\u00f6fel","year":"2018","unstructured":"H\u00f6fel L, Eppler B, Storf M, Schn\u00f6bel-M\u00fcller E, Haas J-P, H\u00fcgle B (2018) Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing\u2013treatment protocol and preliminary results. Pediatr Rheumatol 16:1\u20136","journal-title":"Pediatr Rheumatol"},{"key":"5802_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, Van Vollenhoven RF, De Wit M (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"key":"5802_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","volume":"29","author":"H Kameda","year":"2019","unstructured":"Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, Tomita T, Harigai M, Suzuki Y (2019) Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 29:31\u201340","journal-title":"Mod Rheumatol"},{"key":"5802_CR23","first-page":"88","volume":"10","author":"A \u00c7efle","year":"2018","unstructured":"\u00c7efle A, Keser G, Terzio\u011flu E, Ertenli \u0130, \u0130nan\u00e7 N, Co\u015fan F, Y\u0131lmaz N, \u015eahin A, Can M, Hamuryudan V (2018) Turkish Society for Rheumatology recommendations for the management of rheumatoid arthritis. J Turkish Soc Rheumatol 10:88\u201398","journal-title":"J Turkish Soc Rheumatol"},{"key":"5802_CR24","doi-asserted-by":"crossref","unstructured":"Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, Ravelli A, Taddio A, Zulian F, Cimaz R (2018) Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatric Rheumatology 16:46","DOI":"10.1186\/s12969-018-0255-8"},{"key":"5802_CR25","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3899\/jrheum.090826","volume":"37","author":"ML Becker","year":"2010","unstructured":"Becker ML, Ros\u00e9 CD, Cron RQ, Sherry DD, Bilker WB, Lautenbach E (2010) Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 37:870\u2013875","journal-title":"J Rheumatol"},{"key":"5802_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3899\/jrheum.130738","volume":"41","author":"B Shea","year":"2013","unstructured":"Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 41:1049\u20131060","journal-title":"J Rheumatol"},{"key":"5802_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/adc.2006.094219","volume":"91","author":"O Killeen","year":"2006","unstructured":"Killeen O, Gardner-Medwin J (2006) In juvenile idiopathic arthritis, is folate supplementation effective against methotrexate toxicity at the expense of methotrexate\u2019s efficacy? Arch Dis Child 91:537\u2013538","journal-title":"Arch Dis Child"},{"key":"5802_CR28","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"K Visser","year":"2009","unstructured":"Visser K, Katchamart W, Loza E, Martinez-Lopez J, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma J (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086\u20131093","journal-title":"Ann Rheum Dis"},{"key":"5802_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","volume":"121","author":"SL Morgan","year":"1994","unstructured":"Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcon GS (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 121:833\u2013841","journal-title":"Ann Intern Med"},{"key":"5802_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/clpt.1987.142","volume":"42","author":"MG Myers","year":"1987","unstructured":"Myers MG, Cairns JA, Singer J (1987) The consent form as a possible cause of side effects. Clin Pharmacol Ther 42:250\u2013253","journal-title":"Clin Pharmacol Ther"},{"key":"5802_CR31","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1001\/archinte.1994.00420230150018","volume":"154","author":"GC Lamb","year":"1994","unstructured":"Lamb GC, Green SS, Heron J (1994) Can physicians warn patients of potential side effects without fear of causing those side effects? Arch Intern Med 154:2753\u20132756","journal-title":"Arch Intern Med"},{"key":"5802_CR32","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/BF00846163","volume":"5","author":"LA Morris","year":"1982","unstructured":"Morris LA, Kanouse DE (1982) Informing patients about drug side effects. J Behav Med 5:363\u2013373","journal-title":"J Behav Med"},{"key":"5802_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15265161.2011.652798","volume":"12","author":"RE Wells","year":"2012","unstructured":"Wells RE, Kaptchuk TJ (2012) To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth 12:22\u201329","journal-title":"Am J Bioeth"},{"key":"5802_CR34","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/MIB.0000000000001014","volume":"23","author":"C Dupont-Lucas","year":"2017","unstructured":"Dupont-Lucas C, Grandjean-Blanchet C, Leduc B, Tripcovici M, Larocque C, Gervais F, Jantchou P, Amre D, Deslandres C (2017) Prevalence and risk factors for symptoms of methotrexate intolerance in pediatric inflammatory bowel disease. Inflamm Bowel Dis 23:298\u2013303","journal-title":"Inflamm Bowel Dis"},{"key":"5802_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/OARRR.S263287","volume":"12","author":"H Almalag","year":"2020","unstructured":"Almalag H, Abouzaid HH, Alnaim L, Albaqami J, AlShalhoub R, Almaghlouth I, Dessougi M, Al Harthi A, Bedaiwi M, Alfi E (2020) Risk Factors Associated with Methotrexate Intolerance in Rheumatoid Arthritis Patients. Open Access Rheumatol 12:193\u2013202","journal-title":"Open Access Rheumatol"},{"key":"5802_CR36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jsps.2012.05.004","volume":"20","author":"HM Al-Malaq","year":"2012","unstructured":"Al-Malaq HM, Al-Arfaj HF, Al-Arfaj AS (2012) Adverse drug reactions caused by methotrexate in Saudi population. Saudi Pharm J 20:301\u2013305","journal-title":"Saudi Pharm J"},{"key":"5802_CR37","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-017-3638-1","volume":"36","author":"A Chausset","year":"2017","unstructured":"Chausset A, Fargeix T, Pereira B, Echaubard S, Duquesne A, Desjonqu\u00e8res M, Freychet C, Belot A, Merlin E (2017) MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance. Clin Rheumatol 36:1281\u20131288","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05802-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05802-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:03:52Z","timestamp":1637197432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05802-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5802"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05802-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2021,7,4]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The other authors have indicated they have no potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}